In the spirit of transparency, it is important that we address the rationale behind why certain supplements are developed with ingredients and processes that challenge convention. Recently AOR launched vegan softgels; a line of supplements that allows ultimate absorption of the ingredients due to carrageenan which is a non-medicinal membrane that encapsulates the contents of the supplements. It seemed like an unlikely choice as carrageenan has garnered somewhat of a misinformed and negative reputation even with the safety approval from regulatory authorities. As a company that prides itself on the quality of our ingredients we decided to question the evidence
WITH ANKASCIN – CLINICAL RESEARCH
Dr. Pan’s group recently completed a clinical study to evaluate the use of Ankascin to manage the symptoms of Alzheimer’s disease.
HOW IT WORKS
Antioxidants protect the body against the harmful effects of waste products produced by our cells. These waste products create a state known as oxidative stress, which is a major aspect of both cardiovascular disease and Alzheimer’s disease. Reducing such stress can slow the development of both disorders. Monascin and ankaflavin act as powerful antioxidants. Recent work from Dr. Pan’s lab showed that monascin prevents oxidation of amyloid beta protein, which is a first step in its aggregation into amyloid plaques43. Furthermore, monascin assists the cells of the body to increase the production of various antioxidant genes that also contribute to the protective effect. The net effect of these actions is to reduce both the inflammation and toxicity associated with amyloid beta buildup. Ankaflavin also acts as an anti-inflammatory agent through different mechanisms44. It activates the cellular oxidative stress pathway, which leads cells to respond by producing large quantities of natural antioxidants17.
CLINICAL STUDY FOR THE EFFECT OF ANKASCIN 568 IN ALZHEIMER’S PATIENTS
AUTHORS: Tzu-Ming Pan, Ya-Wen Hsu and colleagues
JOURNAL: Submitted for publication
PUBLICATION YEAR: 2018
DESIGN: Placebo-controlled clinical study
POPULATION: 10 patients with mild to moderate Alzheimer’s disease
DOSE: 440 mg of Ankascin per day
DURATION: 10 months
RESULTS: After 9 months of treatment, patients receiving Ankascin showed fewer signs of dementia as compared to a decline in the control group. Ankascin patients also exhibited less distress and agitation, in addition to a reduction in blood LDL cholesterol and triglycerides.
KEY CONCLUSIONS: Ankascin may be effective in managing symptoms associated with Alzheimer’s disease.
17. Hsu, W.-H. H., Lee, B.-H. H., Huang, Y.-C. C., Hsu, Y.-W. W. and Pan, T.-M. M. (2012). Ankaflavin, a novel Nrf-2 activator for attenuating allergic airway inflammation. Free Radical Biology and Medicine 53: 1643–1651
43. Shi, Y. C., Pan, T. M. and Liao, V. H. C. (2016). Monascin from Monascus-Fermented Products Reduces Oxidative Stress and Amyloid-β Toxicity via DAF-16/FOXO in Caenorhabditis elegans. Journal of Agricultural and Food Chemistry 64: 7114–7120 iorit
44. Hsu, L.-C., Hsu, Y.-W., Liang, Y.-H., Kuo, Y.-H. and Pan, T.-M. (2011). Anti-tumor and Anti-inflammatory Properties of Ankaflavin and Monaphilone A from Monascus purpureus NTU 568. Journal of Agricultural and Food Chemistry 59: 1124–1130 ity50 \lsdlo